IOL Chemicals and Pharmaceuticals 미래 성장

Future 기준 확인 4/6

IOL Chemicals and Pharmaceuticals (는) 각각 연간 29.2% 및 10.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 29.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 10.5% 로 예상됩니다.

주요 정보

29.2%

수익 성장률

29.2%

EPS 성장률

Pharmaceuticals 수익 성장	17.5%
매출 성장률	10.6%
향후 자기자본 수익률	10.5%
애널리스트 커버리지	Low
마지막 업데이트	20 Jan 2025

최근 미래 성장 업데이트

Recent updates

Investors Still Aren't Entirely Convinced By IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Earnings Despite 26% Price Jump

Dec 20

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Has A Somewhat Strained Balance Sheet

Nov 19

A Piece Of The Puzzle Missing From IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Share Price

Sep 11

Is There An Opportunity With IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) 34% Undervaluation?

Jun 12

Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?

Aug 30

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Has A Pretty Healthy Balance Sheet

May 18

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Will Pay A Dividend Of ₹4.00

Feb 10

Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?

Jun 07

Calculating The Intrinsic Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)

May 07

Do IOL Chemicals and Pharmaceuticals's (NSE:IOLCP) Earnings Warrant Your Attention?

May 04

Is IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP) An Attractive Dividend Stock?

Mar 13

Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?

Feb 23

Should You Rely On IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) Earnings Growth?

Feb 08

IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Jan 27

How Does IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) CEO Salary Compare to Peers?

Jan 15

Estimating The Intrinsic Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)

Jan 02

Shareholders of IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Must Be Delighted With Their 869% Total Return

Dec 21

Is Now The Time To Put IOL Chemicals and Pharmaceuticals (NSE:IOLCP) On Your Watchlist?

Dec 09

These 4 Measures Indicate That IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Is Using Debt Reasonably Well

Nov 24

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Could Be A Buy For Its Upcoming Dividend

Nov 12

Is There More To The Story Than IOL Chemicals and Pharmaceuticals's (NSE:IOLCP) Earnings Growth?

Nov 09

Will Weakness in IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Stock Prove Temporary Given Strong Fundamentals?

Oct 27

Here's What We Think About IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) CEO Pay

Oct 09

Calculating The Fair Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)

Sep 18

Here's Why I Think IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Might Deserve Your Attention Today

Sep 03

Cautious Investors Not Rewarding IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Performance Completely

Aug 16

수익 및 매출 성장 예측

NSEI:IOLCP - 애널리스트의 미래 추정치 및 과거 재무 데이터 (INR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2027	26,731	2,168	N/A	2,934	1
3/31/2026	24,980	1,911	39	2,280	2
3/31/2025	22,547	1,460	377	1,950	2
9/30/2024	20,524	998	-1,586	1,273	N/A
6/30/2024	20,720	1,185	N/A	N/A	N/A
3/31/2024	21,328	1,344	159	2,901	N/A
12/31/2023	22,161	1,716	N/A	N/A	N/A
9/30/2023	22,192	1,723	62	2,582	N/A
6/30/2023	22,153	1,503	N/A	N/A	N/A
3/31/2023	22,171	1,391	-895	1,223	N/A
12/31/2022	22,024	1,041	N/A	N/A	N/A
9/30/2022	22,341	1,204	-538	824	N/A
6/30/2022	22,305	1,353	N/A	N/A	N/A
3/31/2022	21,840	1,677	-602	931	N/A
12/31/2021	20,719	2,132	N/A	N/A	N/A
9/30/2021	20,298	2,879	703	2,228	N/A
6/30/2021	20,254	3,840	N/A	N/A	N/A
3/31/2021	19,670	4,446	2,716	3,798	N/A
12/31/2020	19,481	4,596	N/A	N/A	N/A
9/30/2020	19,463	4,428	2,902	3,779	N/A
6/30/2020	18,618	4,035	N/A	N/A	N/A
3/31/2020	18,945	3,613	3,905	4,708	N/A
12/31/2019	18,753	3,727	N/A	N/A	N/A
9/30/2019	18,423	3,569	N/A	N/A	N/A
6/30/2019	18,163	3,076	N/A	N/A	N/A
3/31/2019	16,853	2,367	2,126	2,732	N/A
12/31/2018	15,506	1,465	N/A	N/A	N/A
9/30/2018	13,350	731	N/A	N/A	N/A
6/30/2018	11,298	391	N/A	N/A	N/A
3/31/2018	9,833	277	N/A	1,197	N/A
12/31/2017	8,891	178	N/A	N/A	N/A
9/30/2017	8,094	100	N/A	N/A	N/A
6/30/2017	8,265	65	N/A	N/A	N/A
3/31/2017	7,107	47	N/A	833	N/A
12/31/2016	6,595	39	N/A	N/A	N/A
9/30/2016	6,197	-74	N/A	N/A	N/A
6/30/2016	6,055	-214	N/A	N/A	N/A
3/31/2016	5,804	-400	N/A	177	N/A
12/31/2015	5,131	-692	N/A	N/A	N/A
9/30/2015	4,377	-890	N/A	N/A	N/A
6/30/2015	4,008	-858	N/A	N/A	N/A
3/31/2015	3,847	-667	N/A	-470	N/A
12/31/2014	4,405	-378	N/A	N/A	N/A
9/30/2014	5,115	-71	N/A	N/A	N/A
6/30/2014	5,452	37	N/A	N/A	N/A
3/31/2014	5,635	33	N/A	784	N/A

애널리스트 미래 성장 예측

수입 대 저축률: IOLCP 의 연간 예상 수익 증가율( 29.2% )이 saving rate( 6.7% 보다 높습니다. ).

수익 vs 시장: IOLCP 의 연간 수익( 29.2% ) Indian 시장( 17.8% 보다 빠르게 성장할 것으로 예상됩니다. 17.8% 연간).

고성장 수익: IOLCP 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: IOLCP 의 수익(연간 10.6% ) Indian 시장( 10.6% 보다 빠르게 성장할 것으로 예상됩니다. 10.6% 연간).

고성장 수익: IOLCP 의 수익(연간 10.6% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: IOLCP 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 10.5 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/01/24 14:33
장 마감 주가	2025/01/24 00:00
수익	2024/09/30
연간 수익	2024/03/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

IOL Chemicals and Pharmaceuticals Limited 3 애널리스트 중 2 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
null null	Antique Stockbroking Ltd.
Rohit Bhat	Batlivala & Karani Securities India Pvt. Ltd.
Kameswari V. S. Chavali	FirstCall Research

IOL Chemicals and Pharmaceuticals 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Price target decreased by 10% to ₹434

Price target decreased by 8.9% to ₹471

Price target increased by 15% to ₹517

Price target increased by 13% to ₹510

Price target increased to ₹575

Price target increased to ₹575

Recent updates

Investors Still Aren't Entirely Convinced By IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Earnings Despite 26% Price Jump

Price target decreased by 10% to ₹434

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Has A Somewhat Strained Balance Sheet

Second quarter 2025 earnings released: EPS: ₹3.26 (vs ₹6.45 in 2Q 2024)

IOL Chemicals and Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 14, 2024

IOL Chemicals and Pharmaceuticals Limited Announces Resignation of Vikas Vij as Chief Executive Officer, Effective 30 September 2024

A Piece Of The Puzzle Missing From IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Share Price

Investor sentiment improves as stock rises 21%

IOL Chemicals and Pharmaceuticals Limited Announces Resignation of Sandhya Mehta as Independent Director

Full year 2024 earnings: EPS and revenues miss analyst expectations

IOL Chemicals and Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 09, 2024

Price target decreased by 8.9% to ₹471

Is There An Opportunity With IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) 34% Undervaluation?

Full year 2024 earnings: EPS and revenues miss analyst expectations

IOL Chemicals and Pharmaceuticals Limited, Annual General Meeting, Aug 23, 2024

IOL Chemicals and Pharmaceuticals Limited to Report Q4, 2024 Results on May 14, 2024

Price target increased by 15% to ₹517

IOL Chemicals and Pharmaceuticals Limited Announces CDE, China Approved Metformin Hydrochloride

IOL Chemicals and Pharmaceuticals Limited Approves Closing of M/S Iol Global Limited, Uk, Wholly Owned Subsidiary of the Company

IOL Chemicals and Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 06, 2024

Second quarter 2024 earnings released: EPS: ₹6.45 (vs ₹2.71 in 2Q 2023)

New major risk - Revenue and earnings growth

IOL Chemicals and Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 08, 2023

Investor sentiment improves as stock rises 17%

Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?

IOL Chemicals and Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 09, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Has A Pretty Healthy Balance Sheet

Price target increased by 13% to ₹510

IOL Chemicals and Pharmaceuticals Receives Cep for Paracetamol to Export in European Market

Full year 2023 earnings: EPS exceeds analyst expectations

Investor sentiment improves as stock rises 19%

Upcoming dividend of ₹4.00 per share at 1.3% yield

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Will Pay A Dividend Of ₹4.00

Third quarter 2023 earnings released: EPS: ₹4.05 (vs ₹6.82 in 3Q 2022)

IOL Chemicals and Pharmaceuticals Limited Declares Interim Dividend for the Fiscal Year 2023, Payable Before 8 March 2023

IOL Chemicals and Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 07, 2023

Investor sentiment improved over the past week

Second quarter 2023 earnings released: EPS: ₹2.71 (vs ₹5.26 in 2Q 2022)

Price target increased to ₹575

IOL Chemicals and Pharmaceuticals Limited Receives EDQM Certification to Supply Pantoprazole Sodium Sesquihydrate API in European Market

IOL Chemicals and Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 14, 2022

Full year 2022 earnings released: EPS: ₹28.56 (vs ₹76.21 in FY 2021)

IOL Chemicals and Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 09, 2022

Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?

Full year 2022 earnings released: EPS: ₹28.56 (vs ₹76.21 in FY 2021)

Now 20% undervalued

IOL Chemicals and Pharmaceuticals Limited Announces Executive Changes

IOL Chemicals and Pharmaceuticals Limited to Report Q4, 2022 Results on May 30, 2022

Calculating The Intrinsic Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)

Price target increased to ₹575

IOL Chemicals and Pharmaceuticals Limited Commences the Commercial Production of 'Paracetamol' with Installed Capacity of 1,800 MTPA Along with Backward Integration of Para Amino Phenol (PAP) with Effect from 22 April 2022

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

Now 23% undervalued after recent price drop

Upcoming dividend of ₹4.00 per share

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

IOL Chemicals and Pharmaceuticals Limited Declares Interim Dividend for the Financial Year 2021-222, Payable Before 5 March 2022

IOL Chemicals and Pharmaceuticals Limited to Report Q3, 2022 Results on Feb 04, 2022

Upcoming dividend of ₹2.00 per share

President of Project recently sold ₹3.5m worth of stock

First quarter 2022 earnings released: EPS ₹11.41 (vs ₹22.30 in 1Q 2021)

Full year 2021 earnings released: EPS ₹76.21 (vs ₹63.51 in FY 2020)

Do IOL Chemicals and Pharmaceuticals's (NSE:IOLCP) Earnings Warrant Your Attention?

Joint MD & Whole Time Director has left the company

IOL Chemicals and Pharmaceuticals Limited Appoints Sanjay Chaturvedi as Chief Executive Officer

Is IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP) An Attractive Dividend Stock?

Investor sentiment improved over the past week